Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2001

View Archived Issues

Additional study needed to support transdermal methylphenidate NDA

Antex Biologics reports major progress in clinical development programs over past year

Novogyne acquires CombiPatch

OraPharma launches Arestin in the U.S. for adjunctive treatment of periodontal disease

Sustained-release naltrexone enters phase II in alcohol-dependent patients

Discovery Laboratories begins phase III IRDS trial for Surfaxin

Demegen completes next step in Periodontix acquisition

ACS news: design and synthesis of novel beta3-adrenoceptor agonists reported by Wyeth-Ayerst

PTI-801, a new drug candidate for chronic pain, enters development at Pain Therapeutics

Integrin antagonists as orally active tumor angiogenesis inhibitors subject of ACS presentation

Sangamo and Onyx to codevelop novel cancer therapeutics

First-in-class indolocarbazole anticancer agent introduced by BMS at ACS and AACR meetings

FDA begins review of Ortec's CCS product for burn patients

U.K. investigators report promising preclinical data for telomerase inhibitors

Second-line antihypertensive combination therapy launched in U.S.

DuPont seeks FDA approval for new formulation of Sustiva

Analogues of p38 MAP kinase inhibitor RPR-200765A with improved profile obtained at Aventis

AstraZeneca begins phase III evaluation of platinum anticancer agent; milestone triggered

J-115814 exerts anorexigenic effects by blocking Y1 receptors

Identification of a small molecule targeting CDK4 with promise for treating tumors

Novel compounds useful as JNK inhibitors patented by Vertex

Positive decision issued in Europe for Reductil obesity treatment

Antitumor isophosphoramide mustard analogues designed at Southern Research Institute

Italian researchers identify new indazolamides with utility particularly in IBS

Potent, broad-spectrum antiviral activity demonstrated by Maruishi compounds

Selective sigma2 receptor ligands patented by Santen

Tularik's arylsulfonanilide derivatives useful as pharmacologically active agents

Metalloproteinase inhibitors from Pfizer for inflammation, cancer, etc.

Newly issued patent covers thymidylate synthase inhibitors synthesized at SUNY

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...